AU2021353968B2 - Compounds and their use in treating cancer - Google Patents

Compounds and their use in treating cancer Download PDF

Info

Publication number
AU2021353968B2
AU2021353968B2 AU2021353968A AU2021353968A AU2021353968B2 AU 2021353968 B2 AU2021353968 B2 AU 2021353968B2 AU 2021353968 A AU2021353968 A AU 2021353968A AU 2021353968 A AU2021353968 A AU 2021353968A AU 2021353968 B2 AU2021353968 B2 AU 2021353968B2
Authority
AU
Australia
Prior art keywords
mmol
pharmaceutically acceptable
compound
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021353968A
Other languages
English (en)
Other versions
AU2021353968A9 (en
AU2021353968A1 (en
Inventor
Sharanjeet Kaur Bagal
Ulf BŐRJESSON
Gavin William COLLIE
Charlene FALLAN
Christoph GREBNER
Thomas George Christopher Hayhow
Jason Grant Kettle
Iacovos Neal MICHAELIDES
Matthew William Dampier PERRY
Robert Ian Storer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2021353968A1 publication Critical patent/AU2021353968A1/en
Publication of AU2021353968A9 publication Critical patent/AU2021353968A9/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Amend patent request/document other than specification (104) Assignors: ASTRAZENECA AB
Application granted granted Critical
Publication of AU2021353968B2 publication Critical patent/AU2021353968B2/en
Priority to AU2025200137A priority Critical patent/AU2025200137A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
AU2021353968A 2020-09-30 2021-09-29 Compounds and their use in treating cancer Active AU2021353968B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200137A AU2025200137A1 (en) 2020-09-30 2025-01-09 Compounds and their use in treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085384P 2020-09-30 2020-09-30
US63/085,384 2020-09-30
PCT/EP2021/076752 WO2022069520A1 (en) 2020-09-30 2021-09-29 Compounds and their use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200137A Division AU2025200137A1 (en) 2020-09-30 2025-01-09 Compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
AU2021353968A1 AU2021353968A1 (en) 2023-06-08
AU2021353968A9 AU2021353968A9 (en) 2024-10-03
AU2021353968B2 true AU2021353968B2 (en) 2024-10-10

Family

ID=78085628

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021353968A Active AU2021353968B2 (en) 2020-09-30 2021-09-29 Compounds and their use in treating cancer
AU2025200137A Pending AU2025200137A1 (en) 2020-09-30 2025-01-09 Compounds and their use in treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200137A Pending AU2025200137A1 (en) 2020-09-30 2025-01-09 Compounds and their use in treating cancer

Country Status (17)

Country Link
US (1) US20230374007A1 (https=)
EP (1) EP4221756A1 (https=)
JP (1) JP2023543299A (https=)
KR (1) KR20230079408A (https=)
CN (1) CN116249554A (https=)
AU (2) AU2021353968B2 (https=)
BR (1) BR112023005708A2 (https=)
CA (1) CA3195695A1 (https=)
CL (1) CL2023000881A1 (https=)
CO (1) CO2023005188A2 (https=)
CR (1) CR20230185A (https=)
DO (1) DOP2023000062A (https=)
EC (1) ECSP23030959A (https=)
IL (1) IL301626A (https=)
MX (1) MX2023003564A (https=)
PE (1) PE20230782A1 (https=)
WO (1) WO2022069520A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141179B (zh) * 2021-03-31 2024-09-13 江苏恒瑞医药股份有限公司 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
CN119301111A (zh) 2022-03-24 2025-01-10 葛兰素史密斯克莱知识产权发展有限公司 作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
USD1018676S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
USD1018746S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
USD1020957S1 (en) * 2022-04-15 2024-04-02 Puttshack LTD Miniature golf hole
USD1018747S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
CN119855812A (zh) * 2022-09-14 2025-04-18 海南先声再明医药股份有限公司 多并环类化合物及其用途
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs
TW202515566A (zh) 2023-06-14 2025-04-16 瑞典商阿斯特捷利康公司 Ｓｍａｒｃａ２降解劑及其用途
MX2025015084A (es) * 2023-06-14 2026-02-03 Astrazeneca Ab Degradadores de smarca2 y usos de estos
WO2025036489A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
IL326555A (en) 2023-09-22 2026-04-01 Glaxosmithkline Ip Dev Ltd Androgen receptor protax
CN117430605A (zh) * 2023-10-26 2024-01-23 广西天铭药业有限公司 一种kras g12c抑制剂amg-510中间体的合成方法
US20250177539A1 (en) * 2023-12-01 2025-06-05 Astrazeneca Ab Er degraders and uses thereof
WO2025125575A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP6509838B2 (ja) 2013-06-26 2019-05-08 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2019057757A1 (en) * 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN120698983A (zh) * 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same

Also Published As

Publication number Publication date
WO2022069520A1 (en) 2022-04-07
JP2023543299A (ja) 2023-10-13
US20230374007A1 (en) 2023-11-23
CL2023000881A1 (es) 2023-11-17
AU2021353968A9 (en) 2024-10-03
AU2025200137A1 (en) 2025-01-30
EP4221756A1 (en) 2023-08-09
AU2021353968A1 (en) 2023-06-08
MX2023003564A (es) 2023-04-04
CO2023005188A2 (es) 2023-05-19
KR20230079408A (ko) 2023-06-07
PE20230782A1 (es) 2023-05-09
DOP2023000062A (es) 2023-05-31
ECSP23030959A (es) 2023-05-31
CN116249554A (zh) 2023-06-09
CR20230185A (es) 2023-06-27
CA3195695A1 (en) 2022-04-07
BR112023005708A2 (pt) 2023-05-02
IL301626A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
AU2021353968B2 (en) Compounds and their use in treating cancer
AU2019267008B2 (en) Tetracyclic heteroaryl compounds
ES3013592T3 (en) Kras g12d inhibitors
ES2551592T3 (es) Pirazolo[1,5-a]piridinas como inhibidores de TRK
CA3198885A1 (en) Azaquinazoline pan-kras inhibitors
US11834453B2 (en) Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
CN119585287A (zh) Kras g12d蛋白水解靶向嵌合体
CA2651363C (en) Triazolopyrazine derivatives useful as anti-cancer agents
CN118561952A (zh) Ras抑制剂
JP2022508108A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤
CN121532183A (zh) Kras g12s和g12c抑制剂
CA3105721A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
CN117903140A (zh) 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
CN121889399A (zh) Kras蛋白水解靶向嵌合体
CA2735932A1 (en) Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
CA2731368A1 (en) 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
CN116670123B (zh) 芳香杂环类化合物、药物组合物及其应用
EA032301B1 (ru) Изоиндолиновые или изохинолиновые соединения, способ их получения и содержащие их фармацевтические композиции
WO2022269531A1 (en) Her2 mutation inhibitors
EP3097095A1 (en) Furo-3-carboxamide derivatives and methods of use
TW202411225A (zh) 化合物及其用途
WO2025242908A2 (en) Novel compounds
CN121532398A (zh) 用于治疗自身免疫性疾病的大环
OA22163A (en) Cyclin-Dependent Kinase 7 Inhibitors.
CA3268634A1 (en) Cyclin-dependent kinase 7 inhibitors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ASTRAZENECA AB

Free format text: FORMER NAME(S): ASTRAZENECA AB

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)